SubsidieMeestersRepurposing a human drug to treat Alzheimer’s disease
This project aims to validate an approved drug that inhibits tau accumulation in Alzheimer's, advancing it towards commercialization as a novel treatment for the disease.
Projectdetails
Introduction
Alzheimer’s disease is a major cause of disability among older adults and represents substantial financial and human costs to patients, families, and societies worldwide. Currently, there is no cure for Alzheimer’s disease.
Need for Novel Treatments
Thus, novel effective treatments need to be developed that target the root causes of Alzheimer’s disease, in particular the pathogenic accumulation of the protein tau.
Breakthrough Achievement
During our ERC project, we achieved a breakthrough by demonstrating that an approved human drug efficiently inhibits pathogenic tau accumulation in several pre-clinical assays.
Drug Characteristics
The identified FDA/EMA-approved small molecule is:
- Orally bioavailable
- Safe in humans
- Reaches the brain at high concentrations
Project Aim
It is the aim of this proof of concept project to provide further pre-clinical validation of the drug and to pursue the needed steps towards IPR protection and commercialization.
Potential Impact
Because no disease-modifying therapy currently exists for Alzheimer’s disease, bringing the novel repurposed drug closer to the market promises an outstanding high gain.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-6-2022 |
| Einddatum | 30-11-2023 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EVpenvoerder
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targetting neutrophil-mediated neurotoxicity for the treatment of Alzheimer's DiseaseThe NeutrAD project aims to develop and commercialize the first disease-modifying Alzheimer's drugs targeting neutrophil-mediated neurotoxicity, with promising results in preclinical models. | ERC Proof of... | € 150.000 | 2022 | Details |
Gamma-secretase allosteric modulation as preventive therapy in Alzheimer’s DiseaseThis project aims to validate gamma-secretase allosteric modulators as safe, effective, and affordable preventative treatments for Alzheimer's Disease using an innovative xenotransplantation model. | ERC Proof of... | € 150.000 | 2024 | Details |
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s diseaseADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Synaptic resilience in Tau-induced neurodegenerationThis project aims to uncover the mechanisms of synaptic remodeling during hibernation to develop therapies that reverse Tau-induced synaptic decline in dementia. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Deciphering Alzheimer’s disease molecular subtypes to advance treatment development.This project aims to identify Alzheimer's disease subtypes through CSF proteomics to develop tailored treatments and theragnostic tools linked to cognitive decline and genetic factors. | ERC Consolid... | € 2.999.934 | 2025 | Details |
Targetting neutrophil-mediated neurotoxicity for the treatment of Alzheimer's Disease
The NeutrAD project aims to develop and commercialize the first disease-modifying Alzheimer's drugs targeting neutrophil-mediated neurotoxicity, with promising results in preclinical models.
Gamma-secretase allosteric modulation as preventive therapy in Alzheimer’s Disease
This project aims to validate gamma-secretase allosteric modulators as safe, effective, and affordable preventative treatments for Alzheimer's Disease using an innovative xenotransplantation model.
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease
ADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients.
Synaptic resilience in Tau-induced neurodegeneration
This project aims to uncover the mechanisms of synaptic remodeling during hibernation to develop therapies that reverse Tau-induced synaptic decline in dementia.
Deciphering Alzheimer’s disease molecular subtypes to advance treatment development.
This project aims to identify Alzheimer's disease subtypes through CSF proteomics to develop tailored treatments and theragnostic tools linked to cognitive decline and genetic factors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug developmentATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Repurposed RoflumilastArega Medical herpositioneert Roflumilast voor vroege fase Alzheimer om het toegankelijk en betaalbaar te maken voor patiënten. | Mkb-innovati... | € 20.000 | 2022 | Details |
Antilichaam voor Parkison behandelingAugmentor Management ontwikkelt een specifiek antilichaam tegen alphasynucleine oligomeren om de progressie van de ziekte van Parkinson te remmen en zoekt haalbaarheid voor verder onderzoek. | Mkb-innovati... | € 20.000 | 2021 | Details |
Towards the clinical implementation of TREM2 Microglia Engineering for treating DementiaSTREM2MEDS aims to transition a novel gene therapy for Alzheimer’s and Nasu-Hakola Diseases from preclinical validation to a Phase I clinical trial, targeting TREM2 dysfunction in microglia. | EIC Transition | € 2.499.721 | 2024 | Details |
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions. | EIC Accelerator | € 1.636.639 | 2024 | Details |
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development
ATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization.
Repurposed Roflumilast
Arega Medical herpositioneert Roflumilast voor vroege fase Alzheimer om het toegankelijk en betaalbaar te maken voor patiënten.
Antilichaam voor Parkison behandeling
Augmentor Management ontwikkelt een specifiek antilichaam tegen alphasynucleine oligomeren om de progressie van de ziekte van Parkinson te remmen en zoekt haalbaarheid voor verder onderzoek.
Towards the clinical implementation of TREM2 Microglia Engineering for treating DementiaS
TREM2MEDS aims to transition a novel gene therapy for Alzheimer’s and Nasu-Hakola Diseases from preclinical validation to a Phase I clinical trial, targeting TREM2 dysfunction in microglia.
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)
GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions.